(Q37481337)

20 August 2017

1 reference

title

Novel camptothecin derivatives as topoisomerase I inhibitors (English)

1 reference

20 August 2017

Stefano Moro

2

0 references

author name string

Serena Basili

series ordinal

1

1 reference

20 August 2017

language of work or name

English

0 references

publication date

1 May 2009

1 reference

Expert Opinion on Therapeutic Patents

20 August 2017

published in

1 reference

20 August 2017

volume

19

1 reference

20 August 2017

issue

5

1 reference

20 August 2017

page(s)

555-574

1 reference

Synthesis of water-soluble (aminoalkyl)camptothecin analogs: inhibition of topoisomerase I and antitumor activity

20 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543770902773437

Modification of the hydroxy lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902773437

Camptothecin analogues with enhanced antitumor activity at acidic pH.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902773437

BCRP/MXR/ABCP expression in topotecan-resistant human breast carcinoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902773437

Mechanisms of cellular resistance to camptothecins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902773437

Eukaryotic DNA topoisomerases I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902773437

Mechanism of the reaction catalyzed by the DNA untwisting enzyme: Attachment of the enzyme to 3′-terminus of the nicked DNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902773437

Topoisomerase I inhibitors: camptothecins and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902773437

Tumor cell death induced by topoisomerase-targeting drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902773437

SUMO-1 conjugation to topoisomerase I: A possible repair response to topoisomerase-mediated DNA damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902773437

Next generation topoisomerase I inhibitors: Rationale and biomarker strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902773437

Nonlinear partial differential equations and applications: The mechanism of topoisomerase I poisoning by a camptothecin analog

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902773437

Synthesis and mechanism of action studies of a series of norindenoisoquinoline topoisomerase I poisons reveal an inhibitor with a flipped orientation in the ternary DNA-enzyme-inhibitor complex as determined by X-ray crystallographic analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902773437

Structures of three classes of anticancer agents bound to the human topoisomerase I-DNA covalent complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902773437

Multicentre phase II and pharmacokinetic study of RFS2000 (9-nitro-camptothecin) administered orally 5 days a week in patients with glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902773437

Clinical phase II study and pharmacological evaluation of rubitecan in non-pretreated patients with metastatic colorectal cancer-significant effect of food intake on the bioavailability of the oral camptothecin analogue

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902773437

Design, synthesis and development of novel camptothecin drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902773437

A phase I clinical and pharmacokinetic study of the new topoisomerase inhibitor GI147211 given as a 72-h continuous infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902773437

Phase I/pharmacokinetic study of the topoisomerase I inhibitor GG211 administered as a 21-day continuous infusion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902773437

Activity and toxicity of GI147211 in breast, colorectal and non-small-cell lung cancer patients: an EORTC-ECSG phase II clinical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902773437

A phase 1 study of OSI-211 given as an intravenous infusion days 1, 2, and 3 every three weeks in patients with solid cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902773437

Phase I and pharmacokinetic study of a low-clearance, unilamellar liposomal formulation of lurtotecan, a topoisomerase 1 inhibitor, in patients with advanced leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902773437

A new water-soluble camptothecin derivative, DX-8951f, exhibits potent antitumor activity against human tumors in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902773437

Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902773437

DX-8951f, a hexacyclic camptothecin analog, on a daily-times-five schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902773437

Phase I pharmacokinetic, food effect, and pharmacogenetic study of oral irinotecan given as semisolid matrix capsules in patients with solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902773437

Phase I Study and Pharmacokinetics of CPT-11 With 5-Day Continuous Infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902773437

Novel camptothecin derivative BNP1350 in experimental human ovarian cancer: determination of efficacy and possible mechanisms of resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902773437

Phase I dose-finding study and a pharmacokinetic/pharmacodynamic analysis of the neutropenic response of intravenous diflomotecan in patients with advanced malignant tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902773437

Chemical Modification of an Antitumor Alkaloid Camptothecin: Synthesis and Antitumor Activity of 7-C-Substituted Camptothecins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902773437

Concerted escalation of dose and dosing duration in a phase I study of the oral camptothecin gimatecan (ST1481) in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902773437

Novel 7-oxyiminomethyl derivatives of camptothecin with potent in vitro and in vivo antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902773437

Safety, tolerability, and pharmacokinetics of a capsule formulation of DRF-1042, a novel camptothecin analog, in refractory cancer patients in a bridging phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902773437

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902773437

Synthesis and pharmacological evaluation of novel non-lactone analogues of camptothecin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902773437

Novel stable camptothecin derivatives replacing the E-ring lactone by a ketone function are potent inhibitors of topoisomerase I and promising antitumor drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902773437

Novel E-ring camptothecin keto analogues (S38809 and S39625) are stable, potent, and selective topoisomerase I inhibitors without being substrates of drug efflux transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902773437

Plant Antitumor Agents. I. The Isolation and Structure of Camptothecin, a Novel Alkaloidal Leukemia and Tumor Inhibitor from Camptotheca acuminata1,2

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902773437

10.1517/13543770902773437

21 January 2018

Identifiers

DOI

1 reference

20 August 2017

1 reference